



## Case Report

Journal Homepage: <http://crp.tums.ac.ir>

# Concomitant Bilateral Papillary Thyroid Carcinoma and Parathyroid Adenoma

Reza Hajebi<sup>1</sup> , Elham Nazar<sup>2\*</sup> , Shabnam Mashhadi<sup>2</sup>

1. Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

2. Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.



**Citation** Hajebi R, Nazar E, Mashhadi Sh. Concomitant Bilateral Papillary Thyroid Carcinoma and Parathyroid Adenoma. Case Reports in Clinical Practice. 2022; 7(1):21-24.

**Running Title** Papillary Thyroid Carcinoma and Parathyroid Adenoma

**Article info:****Received:** 15 January 2022**Revised:** 31 January 2022**Accepted:** 26 February 2022**Keywords:**

Thyroid carcinoma; Parathyroid adenoma; Coincident; Surgery

**ABSTRACT**

Thyroid malignant neoplasms are the most prevalent cancer of the endocrine system, and their concurrence with parathyroid neoplasms is extremely rare. We report a 69-year-old woman presenting with hypercalcemia and thyroid nodule, which histologic examination revealed bilateral papillary thyroid carcinoma with different variants coincident with parathyroid adenoma. Awareness of concomitant parathyroid and thyroid diseases may help manage patients with hypercalcemia history. So, we recommended a preoperative calcium check in a patient with a thyroid nodule.


**Introduction**

**T**hyroid malignant neoplasms are the most prevalent cancer of the endocrine system; however, they are rarely seen internationally [1, 2]. The rapid growth of its case numbers has been reported in recent years in many countries likewise Iran [3-6]. Besides, few studies have estimated that bilateral thyroid

carcinoma occurrence accounts for a significantly low proportion of thyroid carcinomas [7, 8]. The incidence of primary hyperparathyroidism is estimated at 0.1% in the general population, mainly in multiple endocrine neoplasias (MEN types I and IIa) [9].

Despite several reports regarding synchronous non-medullary thyroid carcinoma and parathyroid hyperplasia, the presence of parathyroid adenoma with papillary

**\* Corresponding Author:****Elham Nazar, MD.****Address:** Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.**E-mail:** [elhamnazar@yahoo.com](mailto:elhamnazar@yahoo.com)



**Figure 1.** Histologic examination revealed papillary thyroid carcinoma, classic variant (right), and papillary thyroid carcinoma, follicular variant (left) (H&E, x400)

carcinoma is extremely rare [10]. Here we further report a sporadic concurrence of bilateral papillary thyroid carcinoma with parathyroid adenoma to raise awareness about cervical mass.


### Case Presentation

A 69-year-old woman presented in the Department of Surgery in Sina Hospital in Tehran in Iran with a 3 months history of painless left cervical mass. She experienced any dyspnea, hoarseness as well as dysphagia either. The patient's family history and past medical history were unremarkable.

A physical exam showed an asymmetric enlarged thyroid gland without palpable lymph nodes. Left thyroid lobe sonography revealed a solid-cystic hetero-echoic nodule measuring 51x20x2 mm. Right thyroid lobe sonography showed a well-circumscribed solid hypoechoic nodule sized 6x3mm. A cystic lesion with internal septa was also found during cervical sonography measuring 38x38x47 mm in the right thoracic inlet. Fine Needle Aspiration (FNA) from the left thyroid lobe nodule was

done, and its cytology findings were suggestive of Papillary Thyroid Carcinoma (PTC).

A thyroid scan showed a multinodular goiter pattern in radioactive iodine absorption, and the Sestamibi scan was negative. An abdominal CT scan showed no lesions on both sides of the Adrenals. The preoperative biochemical profile revealed increased serum calcium (13.9 mg/dl) and parathyroid hormone (PTH) level (7.5 pg/ml), a decrease in serum phosphorus level (2.6 mg/dl), and calcitonin level (3.5 pg/ml). After all, surgery was planned, and the left thyroid lobe was sent to the pathology laboratory in a new state for intra-operative investigation. Frozen sections also reconfirmed foci of PTC without any capsular invasion. So, total thyroidectomy and right thoracic inlet mass resection was performed. The received specimen for pathology examination consists of two separate thyroid lobes which right lobe measuring 6x3x2cm and the left lobe measuring 4x2.5x2cm. One piece of brownish tissue measuring 4x2x1cm and weighing 8 grams is also received. Histological examinations revealed PTC, a classic variant in the left lobe, and PTC, a follicular variant in the right lobe (Figure 1). Right



**Figure 2.** Histologic examination revealed Parathyroid adenoma with uniform round cells and high vascularity (H&E, x400)



thoracic inlet mass is compatible with parathyroid adenoma (Figure 2). The final histological diagnosis was PTC and parathyroid adenoma with no evidence of medullary thyroid carcinoma. After 6 months of follow-up examinations, no recurrence was observed, and the patient is still asymptomatic.

## Discussion

Studies describe that patients undergoing parathyroidectomy may suffer from an additional thyroid disease at 2.5% to 17.5%. Primary hyperparathyroidism is reported from 0.3% to 8.7% in diagnosed thyroid disease [11]. The incidence rate of synchronous non-medullary thyroid carcinoma and primary hyperthyroidism/parathyroid adenoma is unclear, although Leitha et al. reported a 3% prevalence rate [12]. In the same fashion, little evidence is known from bilateral thyroid carcinomas regarding concurrence with parathyroid adenomas.

Lee et al.'s report showed that primary hyperparathyroidism was diagnosed before thyroid carcinoma based on histopathology findings [13]. Therefore, our case was confirmed by histopathology after parathyroidectomy. Surprisingly, this report is the single coexistence of bilateral & bivarient papillary thyroid carcinoma and parathyroid adenoma. Several hypotheses have been announced to clarify this sporadic synchronism. Head and neck radiation exposure has been studied, showing controversial impacts [14-16].

Higher angiogenesis factors produced by high PTH levels with hypercalcemia may promote the coexistence of PTC and parathyroid adenomas [17]. Still, PTH was in a normal range in our case, and only a mild calcium level increase was seen. Bilateral papillary thyroid carcinoma is extremely rare, and its concurrence may exist. Then, laboratory testing, namely; calcium, PTH, phosphorous, and calcitonin level, before surgery assists in a specific diagnosis. This case demonstrates the need for clinical alertness of concurrent parathyroid adenoma and thyroid cancer. Therefore, careful thyroid assessment is recommended for all patients with hypercalcemia.

## Conclusion

Although the pathological relationship between parathyroid and thyroid diseases is common, an association between parathyroid adenoma and thyroid cancer is rare. So, in patients with suspicious thyroid nodules and mild hypercalcemia, the possibility of thyroid carcinoma and occult parathyroid neoplasm can be considered.

## Ethical Considerations

### Compliance with ethical guidelines

There were no ethical considerations to be considered in this research.

### Funding

This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

### Conflict of interest

The authors declared no conflict of interest.

### Acknowledgments

The authors would like to thank the research development center of Sina hospital.

## References

- [1] Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer incidence in five continents. Volume IX. IARC Scientific Publications. 2008; (160):1-837. [PMID]
- [2] Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. *Cancer Epidemiology, Biomarkers & Prevention*. 2009; 18(4):1092-100. [DOI:10.1158/1055-9965.EPI-08-0976] [PMID] [PMCID]
- [3] Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer Causes Control*. 2009; 20(5):525-31. [DOI:10.1007/s10552-008-9260-4] [PMID] [PMCID]
- [4] Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. *Cancer Epidemiology, Biomarkers & Prevention*. 2009; 18(3):784-91. [DOI:10.1158/1055-9965.EPI-08-0960] [PMID] [PMCID]
- [5] Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: Time trends and age-period-cohort effects. *British Journal of Cancer*. 2001; 85(9):1335-9. [DOI:10.1054/bjoc.2001.2061] [PMID] [PMCID]
- [6] Hajizadeh N, Pourhoseingholi M, Baghestani A. Incidence rate of thyroid cancer in Iranian population, trend analysis from 2003 to 2009. *International Journal of Epidemiologic Research*. 2015; 2(1):12-7. [http://ijer.skums.ac.ir/article\\_10627.html](http://ijer.skums.ac.ir/article_10627.html)
- [7] Wu Y. The clinical application of central neck lymph nodes dissection. *J Surg Concepts Pract*. 2003; 8:293. [https://www.researchgate.net/publication/285977427\\_The\\_clinical\\_application\\_of\\_central\\_neck\\_lymph\\_node\\_dissection](https://www.researchgate.net/publication/285977427_The_clinical_application_of_central_neck_lymph_node_dissection)

- [8] Wang W, Gu J, Shang J, Wang K. Correlation analysis on central lymph node metastasis in 276 patients with cNO papillary thyroid carcinoma. *International Journal of Clinical and Experimental Pathology*. 2013; 6(3):510-15. [PMID] [PMCID]
- [9] Silverberg SJ, Bilezikian JP. Asymptomatic primary hyperparathyroidism: A medical perspective. *Surgical Clinics of North American*. 2004; 84:787-801. [DOI:10.1016/j.suc.2004.03.002] [PMID]
- [10] Morita SY, Somervell H, Umbricht CB, Dackiw AP, Zeiger MA. Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. *Surgery* 2008; 144(6):862-6. [DOI:10.1016/j.surg.2008.07.029] [PMID]
- [11] Kissin M, Bakst H. Co-existing myxedema and hyperparathyroidism; Case report. *The Journal of Clinical Endocrinology & Metabolism*. 1947; 7(2):152-8. [DOI:10.1210/jcem-7-2-152] [PMID]
- [12] Leitha T, Staudenherz A. Concomitant hyperparathyroidism and non-medullary thyroid cancer, with a review of the literature. *Clinical Nuclear Medicine*. 2003; 28(2):113-7. [DOI:10.1097/01.rlu.0000048680.30820.52] [PMID]
- [13] Lee YS, Nam KH, Chung WY, Chang HS, Park CS. Coexistence of parathyroid adenoma and papillary thyroid carcinoma. *Journal of the Korean Surgical Society*. 2011; 81:316-20. [DOI:10.4174/jkss.2011.81.5.316] [PMID] [PMCID]
- [14] Prinz RA, Barbato AL, Braithwaite SS, Brooks MH, Lawrence AM, Paloyan E. Prior irradiation and the development of coexistent differentiated thyroid cancer and hyperparathyroidism. *Cancer*. 1982; 49(5):874-7. [DOI:10.1002/1097-0142(19820301)49:5%3C874::aid-cncr2820490509%3E3.0.co;2-d] [PMID]
- [15] Mihailescu D, Shore-Freedman E, Mukani S, Lubin J, Ron E, Schneider AB. Multiple neoplasms in an irradiated cohort: Pattern of occurrence and relationship to thyroid cancer outcome. *The Journal of Clinical Endocrinology & Metabolism*. 2002; 87(7):3236-41. [DOI:10.1210/jcem.87.7.8701] [PMID]
- [16] LiVolsi VA, LoGerfo P, Feind CR. Coexistent parathyroid adenomas and thyroid carcinoma. Can radiation be blamed? *Archives of Surgery*. 1978; 113(3):285-6. [DOI:10.1001/arch-surg.1978.01370150057010] [PMID]
- [17] Beebeejaun M, Chinnasamy E, Wilson P, Sharma A, Beharry N, Bano G. Papillary carcinoma of the thyroid in patients with primary hyperparathyroidism: Is there a link? *Medical Hypotheses*. 2017; 103:100-4. [DOI:10.1016/j.mehy.2017.04.016] [PMID]